{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:49:56Z","timestamp":1780404596724,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.breast.2022.12.035","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T17:18:39Z","timestamp":1672334319000},"page":"102-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-3495","authenticated-orcid":false,"given":"Gauthier","family":"Glemarec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Lacaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Cabarrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Aziza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Jouve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slimane","family":"Zerdoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Massabeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Esteyrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mony","family":"Ung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Izar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Chira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2022.12.035_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/1477-7819-12-344","article-title":"Factors responsible for long-term survival in metastatic breast cancer","volume":"12","author":"Kontani","year":"2014","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.breast.2022.12.035_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2022.12.035_bib3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jnci\/djq029","article-title":"International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?","volume":"102","author":"Pagani","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2022.12.035_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab010","article-title":"Characterization of oligometastatic disease in a real-world nationwide cohort of 3447 patients with de Novo metastatic breast cancer","volume":"5","author":"Steenbruggen","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.breast.2022.12.035_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.breast.2022.12.035_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"Hellman","year":"1995","journal-title":"Oligometastases. JCO"},{"key":"10.1016\/j.breast.2022.12.035_bib7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Hellman","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.breast.2022.12.035_bib8","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2022.12.035_bib9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.breast.2017.02.003","article-title":"Systematic review of early and long-term outcome of liver resection for metastatic breast cancer: is there a survival benefit?","volume":"32","author":"Yoo","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.breast.2022.12.035_bib10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00270-016-1301-x","article-title":"Percutaneous thermal ablation of breast cancer metastases in oligometastatic patients","volume":"39","author":"Barral","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.breast.2022.12.035_bib11","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1470-2045(12)70510-7","article-title":"Stereotactic body radiotherapy for oligometastases","volume":"14","author":"Tree","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2022.12.035_bib12","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrclinonc.2012.166","article-title":"Stereotactic body radiotherapy treatment of extracranial metastases","volume":"9","author":"Salama","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.breast.2022.12.035_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.radonc.2021.09.031","article-title":"Stereotactic body radiotherapy to treat breast cancer oligometastases: a systematic review with meta-analysis","volume":"164","author":"Viani","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.breast.2022.12.035_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/1367159","article-title":"Patterns of progression in metastatic estrogen receptor positive breast cancer: an argument for local therapy","volume":"2017","author":"Kelly","year":"2017","journal-title":"International Journal of Breast Cancer"},{"key":"10.1016\/j.breast.2022.12.035_bib15","unstructured":"Moossdorff M. Contralateral lymph node recurrence in breast cancer: regional event rather than distant metastatic disease. A systematic review of the literature n.d. https:\/\/www.clinicalkey.fr\/#!\/content\/playContent\/1-s2.0-S0748798315004734?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0748798315004734%3Fshowall%3Dtrue&referrer=https:%2F%2Fpubmed.ncbi.nlm.nih.gov%2F (accessed February 25, 2021)."},{"key":"10.1016\/j.breast.2022.12.035_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijrobp.2004.12.060","article-title":"CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan","volume":"63","author":"Chapet","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2022.12.035_bib17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.radonc.2013.10.010","article-title":"Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines","volume":"110","author":"Gr\u00e9goire","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.breast.2022.12.035_bib18","series-title":"Mise \u00e0 jour 2021 des recommandations du GEFPICS pour l\u2019\u00e9valuation du statut HER2 dans les cancers infiltrants du sein en France","author":"Franchet","year":"2021"},{"key":"10.1016\/j.breast.2022.12.035_bib19","series-title":"Common terminology Criteria for adverse events","first-page":"155","year":"2017"},{"key":"10.1016\/j.breast.2022.12.035_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2022.12.035_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2017.12.012","article-title":"Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group","volume":"91","author":"deSouza","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2022.12.035_bib22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.breast.2021.06.010","article-title":"Diagnosis, biology and epidemiology of oligometastatic breast cancer","volume":"59","author":"Lacaze","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.breast.2022.12.035_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2967\/jnumed.120.247882","article-title":"Head-to-Head evaluation of 18F-FES and 18F-FDG PET\/CT in metastatic invasive lobular breast cancer","volume":"62","author":"Ulaner","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2022.12.035_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","article-title":"Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial","volume":"126","author":"Trovo","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.breast.2022.12.035_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.radonc.2018.11.022","article-title":"Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade","volume":"131","author":"Milano","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.breast.2022.12.035_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.breast.2019.10.016","article-title":"Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial","volume":"49","author":"David","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.breast.2022.12.035_bib27","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2022.12.035_bib28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3857\/roj.2015.33.4.301","article-title":"Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy","volume":"33","author":"Yoo","year":"2015","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.breast.2022.12.035_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.breast.2015.12.002","article-title":"Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer","volume":"26","author":"Scorsetti","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.breast.2022.12.035_bib30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2021.06.012","article-title":"Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: treatment indication matters","volume":"161","author":"Tan","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.breast.2022.12.035_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102114","article-title":"Prognostic factors in patients with oligometastatic breast cancer - a systematic review","volume":"91","author":"van Ommen-Nijhof","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2022.12.035_bib32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.breast.2022.03.010","article-title":"The continuing conundrum in oligometastatic breast carcinoma: a real-world data","volume":"63","author":"Selvarajan","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.breast.2022.12.035_bib33","doi-asserted-by":"crossref","DOI":"10.1007\/s12282-021-01240-1","article-title":"Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report","author":"Nagasaki","year":"2021","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2022.12.035_bib34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-med-081313-121208","article-title":"The DNA damage response: implications for tumor responses to radiation and chemotherapy","volume":"66","author":"Goldstein","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.breast.2022.12.035_bib35","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13046-020-01693-w","article-title":"CDK4\/6 inhibitors: a novel strategy for tumor radiosensitization","volume":"39","author":"Yang","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.breast.2022.12.035_bib36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ctro.2020.11.010","article-title":"CDK 4\/6 inhibitors combined with radiotherapy: a review of literature","volume":"26","author":"Bosacki","year":"2021","journal-title":"Clinical and Translational Radiation Oncology"},{"key":"10.1016\/j.breast.2022.12.035_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.07.005","article-title":"Radiation therapy with cyclin-dependent kinase 4\/6 inhibitors: a multi-institutional safety and toxicity study","author":"Al-Rashdan","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2022.12.035_bib38","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2022.12.035_bib39","first-page":"1007","article-title":"NRG-BR002: a phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.breast.2022.12.035_bib40","series-title":"Phase III randomized controlled trial and economic evaluation of stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic (1-3 metastases) cancer (SABR-COMET-3)","author":"Olson","year":"2021"},{"key":"10.1016\/j.breast.2022.12.035_bib41","series-title":"Multicentric phase III trial of superiority of stereotactic body radiation therapy in patients with metastatic breast cancer in first-line treatment","author":"Roussy","year":"2018"},{"key":"10.1016\/j.breast.2022.12.035_bib42","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1002\/ijc.33152","article-title":"Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China","volume":"147","author":"Lan","year":"2020","journal-title":"Int J Cancer"}],"updated-by":[{"DOI":"10.1016\/j.breast.2023.03.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000}}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977622002351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977622002351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T21:52:20Z","timestamp":1677102740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977622002351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":42,"alternative-id":["S0960977622002351"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2022.12.035","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.breast.2023.03.011","asserted-by":"object"}]},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2022.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}